UNSPSC 51385201: Fluquazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H10ClF3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31YX4A42L4, chemically known as 2(1h)-quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- but generally known as fluquazone, which bears US NIH Compound Identifier 219069. European Medicines Agency schedules Fluquazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07741MIG.

UNSPSC 51385201 Fluquazone is a Commodity code that does not align with the state and local procurement activity tagged under it. The recent solicitations—for naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and over-the-counter products—address pharmaceutical procurement broadly but do not reference fluquazone or chemically related compounds. The code itself names a single agricultural or industrial chemical, yet the tagged opportunities reflect public health and pharmacy benefit contracting. State and local governments are acquiring emergency response medications, pharmacy benefit management services, and generic pharmaceutical inventories through these solicitations, not fluquazone. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), representing the typical mix of public health and general purchasing infrastructure.

Recent activity spans Florida, Texas, and Minnesota, with the Minnesota MMCAP cooperative extending to Oregon. The Seminole County IFB (IFB60459723LAS) posted June 30, 2026, with response due July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; bidders must provide unit costs and comply with E-Verify and drug-free workplace certification. The Texas HHS RFI (HHS0017013), posted April 3, 2026, gathers vendor capabilities for direct-to-manufacturer prescription programs serving state employee and retiree plans. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026, with responses due March 26, 2026, establishes multiple contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers, requiring compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The code shows little relevant recent activity; the mismatch between the commodity name and the procurement substance suggests a tagging error in the state and local procurement database.